• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® ADPR Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • CD38 Assay System
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human CD38 Enzyme
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • ATPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay System
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • p97 Assays – Application
      • Ketohexokinase Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
      • WRN Exonuclease Assays – Application
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Transcreener ADP Assay Enables Evaluation of NIK Inhibitors in Lupus Drug Discovery

by Bellbrook Labs / Wednesday, 07 November 2018 / Published in HTS Assays, Success Stories
Lupus NIK Inhibitors

 

Systemic lupus erythematosus (SLE), or lupus, takes a devastating toll. An autoimmune disease that triggers a dysfunctional immune system to attack its own tissues, SLE strikes young women most often — about 4 to 12 times more frequently than men — with women aged 15 to 45 being at highest risk. Both genetic and environmental risk factors are suspected.[1]

Widespread tissue damage can affect the joints, kidneys, skin, lungs, brain, and blood vessels. Painful flares can be debilitating, resulting in overwhelming fatigue, rashes, and inflammation and greatly limiting both quality of life and ability to work.[2]

NIK as a Drug Target

The pathogenesis of SLE is mediated by NF-κB-inducing kinase (NIK), which regulates signaling downstream of tumor necrosis factor (TNF) family members. These TNF members include B cell-activating factor (BAFF) and CD40, which are essential for B cell survival and differentiation to auto-antibody-producing plasma cells;[3] TNF-related weak inducer of apoptosis (TWEAK), which controls chronic kidney inflammation and disease that occurs as a consequence of SLE;[4] and the T-cell co-stimulatory molecule OX40L, which expression quantitative trait locus data has shown is highly expressed in people with SLE.[5],[6]

Identifying small molecule NIK inhibitors is of high interest for development of novel treatments for SLE. Due to increasing prevalence of the disease, the global market for SLE therapeutic agents has been estimated to nearly triple from $1.2 B in 2015 to $3.2 B by 2025.[7]

Search for NIK Inhibitors

A study published by researchers at Genentech describes an analysis for small molecule NIK inhibitors that were tested using a mouse model of SLE.[8]  A compound referred to as NIK SMI was identified through a medicinal chemistry optimization program. Brightbill et al. used the Transcreener ADP² Kinase Assay to monitor the ability of NIK to catalyze the hydrolysis of adenosine-5’-triphosphate (ATP) in the presence of test compounds. Tracer displaced by the ADP generated during the NIK reaction caused a decrease in fluorescence polarization that was measured by laser excitation at 633 nm, allowing calculation of equilibrium dissociation constant (Ki) values for the test compounds.  The analysis found that NIK SMI1 strongly inhibits human NIK enzymatic activity, and was roughly 1.7-fold less potent when tested with murine NIK.[8]

The authors interpret their in vitro and in vivo data as indicating that inhibition of NIK in the mouse model of SLE mimics the pharmacological effects of BAFF blockade. Blocking BAFF signaling is the premise of belimumab, the only new therapy for lupus that has been approved in half a century. Additionally, NIK inhibition was associated with changes in pro-inflammatory gene expression patterns in the kidney and reduced renal pathology as well as changes in T cell parameters in the spleen.[8]

While more work remains to be done, a strategy to identify additional potential novel SLE drug candidates is an encouraging development. Moving forward will require careful evaluation of NIK inhibitors and other candidates at both the in vitro and in vivo level. Sensitive, HTS-amenable assays play an important role in this process.

– Robyn M. Perrin, PhD

References

[1] Gergianaki I, Bertsias G. 2018. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. Front Med (Lausanne). 5:161.

[2] Jolly M, Pickard SA, Mikolaitis RA, Rodby RA, Sequeira W, Block JA. 2010.  Lupus QoL-US benchmarks for US patients with systemic lupus erythematosus. J Rheumatol. 37(9):1828–1833.

[3] Groom, JR, et al. 2007. BAFF and MyD88 signals promote a lupus-like disease independent of T cells. J. Exp. Med. 204:1959–1971.

[4] Winkles, JA. 2008. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug Discov. 7:411–425.

[5] Cunninghame Graham, DS, et al. 2008. Polymorphism at the TNF superfamily gene TNFSF4 confers susceptibility to systemic lupus erythematosus. Nat. Genet. 40:83–89

[6] Rajabi P, Alaee M, Mousavizadeh K, Samadikuchaksaraei A. 2012. Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritis. Inflamm. Res. 61:1347–1354.

[7] “Lupus market will reach $3.2 billion by 2025, driven by new first-in-class products,” GlobalData, January 17, 2018. https://www.globaldata.com/lupus-market-will-reach-3-2-billion-2025-driven-new-first-class-products-says-globaldata/

[8] Brightbill HD, et al. 2018. NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus. Nat. Commun. 9:179.

Tagged under: kinase assay, NIK Inhibitors, Transcreener ADP Kinase Assay

What you can read next

Pink Stethascope DOT1L Breast Cancer Target 420 X 280
How a Methyltransferase Activity Assay Could Help Identify Novel Breast Cancer Treatments
SLAS 2019
BellBrook Labs Recap of SLAS 2019 in Washington DC.
Inhibitors of ENPP1 SLAS Discovery
New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Preview of DNA Damage Repair Webinar

    [Webinar] Targeting DNA Damage Repair for Drug Discovery Using the Transcreener ADPR® Assay

    Interested in DNA damage repair pathways for dr...
  • Calculating MAPK14 Residence Time

    Transcreener® ADP2 Assay Delivers Precise Measurement of Functional MAPK14 Residence Time

    Researchers at the University of Tubingen use T...
  • DDX1 as a versatile RNA Helicase

    DDX1: A Versatile RNA Helicase

    DDX1 (Dead-Box Helicase 1) belongs to the DEAD-...
  • RAB2 Transports Membrane Bound Vesicles

    Investigating RAB2 as a Vesicle Transporter & Autophagy Initiator

    RAB2 is part of the RAB family of small GTPases...
  • PARP1 as a Hero vs Villain

    Is PARP1 a Hero or Villain?

    Not counting histones, PARP1 [Poly(ADP-ribose) ...

Archives

BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP